Cargando…

Angiotensin II Receptor 1 Blockage Limits Brain Damage and Improves Functional Outcome After Brain Injury in Aged Animals Despite Age-Dependent Reduction in AT1 Expression

Traumatic brain injury (TBI) is a frequent pathology associated with poor neurological outcome in the aged population. We recently observed accelerated cerebral inflammation in aged mice in response to TBI. Candesartan is a potent specific inhibitor of angiotensin II receptor type 1 (AT1) which limi...

Descripción completa

Detalles Bibliográficos
Autores principales: Timaru-Kast, Ralph, Gotthardt, Philipp, Luh, Clara, Huang, Changsheng, Hummel, Regina, Schäfer, Michael K. E., Thal, Serge C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499023/
https://www.ncbi.nlm.nih.gov/pubmed/31105549
http://dx.doi.org/10.3389/fnagi.2019.00063
_version_ 1783415731164020736
author Timaru-Kast, Ralph
Gotthardt, Philipp
Luh, Clara
Huang, Changsheng
Hummel, Regina
Schäfer, Michael K. E.
Thal, Serge C.
author_facet Timaru-Kast, Ralph
Gotthardt, Philipp
Luh, Clara
Huang, Changsheng
Hummel, Regina
Schäfer, Michael K. E.
Thal, Serge C.
author_sort Timaru-Kast, Ralph
collection PubMed
description Traumatic brain injury (TBI) is a frequent pathology associated with poor neurological outcome in the aged population. We recently observed accelerated cerebral inflammation in aged mice in response to TBI. Candesartan is a potent specific inhibitor of angiotensin II receptor type 1 (AT1) which limits cerebral inflammation and brain damage in juvenile animals after experimental TBI. In the present study, we show significantly lower posttraumatic AT1 mRNA levels in aged (21 months) compared to young (2 months) mice. Despite low cerebral At1 expression, pharmacologic blockade by treatment with candesartan [daily, beginning 30 min after experimental TBI by controlled cortical impact (CCI)] was highly effective in both young and aged animals and reduced histological brain damage by −20% after 5 days. In young mice, neurological improvement was enhanced by AT1 inhibition 5 days after CCI. In older animals, candesartan treatment reduced functional impairment already on day 3 after TBI and post-traumatic body weight (BW) loss was attenuated. Candesartan reduced microglia activation (−40%) in young and aged animals, and neutrophil infiltration (−40% to 50%) in aged mice, whereas T-cell infiltration was not changed in either age group. In young animals, markers of anti-inflammatory microglia M2a polarization [arginase 1 (Arg1), chitinase3-like 3 (Ym1)] were increased by candesartan at days 1 and 5 after insult. In older mice 5 days after insult, expression of Arg1 was significantly higher independently of the treatment, whereas Ym1 gene expression was further enhanced by AT1 inhibition. Despite age-dependent posttraumatic differences in At1 expression levels, inhibition of AT1 was highly effective in a posttreatment paradigm. Targeting inflammation with candesartan is, therefore, a promising therapeutic strategy to limit secondary brain damage independent of the age.
format Online
Article
Text
id pubmed-6499023
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-64990232019-05-17 Angiotensin II Receptor 1 Blockage Limits Brain Damage and Improves Functional Outcome After Brain Injury in Aged Animals Despite Age-Dependent Reduction in AT1 Expression Timaru-Kast, Ralph Gotthardt, Philipp Luh, Clara Huang, Changsheng Hummel, Regina Schäfer, Michael K. E. Thal, Serge C. Front Aging Neurosci Neuroscience Traumatic brain injury (TBI) is a frequent pathology associated with poor neurological outcome in the aged population. We recently observed accelerated cerebral inflammation in aged mice in response to TBI. Candesartan is a potent specific inhibitor of angiotensin II receptor type 1 (AT1) which limits cerebral inflammation and brain damage in juvenile animals after experimental TBI. In the present study, we show significantly lower posttraumatic AT1 mRNA levels in aged (21 months) compared to young (2 months) mice. Despite low cerebral At1 expression, pharmacologic blockade by treatment with candesartan [daily, beginning 30 min after experimental TBI by controlled cortical impact (CCI)] was highly effective in both young and aged animals and reduced histological brain damage by −20% after 5 days. In young mice, neurological improvement was enhanced by AT1 inhibition 5 days after CCI. In older animals, candesartan treatment reduced functional impairment already on day 3 after TBI and post-traumatic body weight (BW) loss was attenuated. Candesartan reduced microglia activation (−40%) in young and aged animals, and neutrophil infiltration (−40% to 50%) in aged mice, whereas T-cell infiltration was not changed in either age group. In young animals, markers of anti-inflammatory microglia M2a polarization [arginase 1 (Arg1), chitinase3-like 3 (Ym1)] were increased by candesartan at days 1 and 5 after insult. In older mice 5 days after insult, expression of Arg1 was significantly higher independently of the treatment, whereas Ym1 gene expression was further enhanced by AT1 inhibition. Despite age-dependent posttraumatic differences in At1 expression levels, inhibition of AT1 was highly effective in a posttreatment paradigm. Targeting inflammation with candesartan is, therefore, a promising therapeutic strategy to limit secondary brain damage independent of the age. Frontiers Media S.A. 2019-04-26 /pmc/articles/PMC6499023/ /pubmed/31105549 http://dx.doi.org/10.3389/fnagi.2019.00063 Text en Copyright © 2019 Timaru-Kast, Gotthardt, Luh, Huang, Hummel, Schäfer and Thal. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Timaru-Kast, Ralph
Gotthardt, Philipp
Luh, Clara
Huang, Changsheng
Hummel, Regina
Schäfer, Michael K. E.
Thal, Serge C.
Angiotensin II Receptor 1 Blockage Limits Brain Damage and Improves Functional Outcome After Brain Injury in Aged Animals Despite Age-Dependent Reduction in AT1 Expression
title Angiotensin II Receptor 1 Blockage Limits Brain Damage and Improves Functional Outcome After Brain Injury in Aged Animals Despite Age-Dependent Reduction in AT1 Expression
title_full Angiotensin II Receptor 1 Blockage Limits Brain Damage and Improves Functional Outcome After Brain Injury in Aged Animals Despite Age-Dependent Reduction in AT1 Expression
title_fullStr Angiotensin II Receptor 1 Blockage Limits Brain Damage and Improves Functional Outcome After Brain Injury in Aged Animals Despite Age-Dependent Reduction in AT1 Expression
title_full_unstemmed Angiotensin II Receptor 1 Blockage Limits Brain Damage and Improves Functional Outcome After Brain Injury in Aged Animals Despite Age-Dependent Reduction in AT1 Expression
title_short Angiotensin II Receptor 1 Blockage Limits Brain Damage and Improves Functional Outcome After Brain Injury in Aged Animals Despite Age-Dependent Reduction in AT1 Expression
title_sort angiotensin ii receptor 1 blockage limits brain damage and improves functional outcome after brain injury in aged animals despite age-dependent reduction in at1 expression
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499023/
https://www.ncbi.nlm.nih.gov/pubmed/31105549
http://dx.doi.org/10.3389/fnagi.2019.00063
work_keys_str_mv AT timarukastralph angiotensiniireceptor1blockagelimitsbraindamageandimprovesfunctionaloutcomeafterbraininjuryinagedanimalsdespiteagedependentreductioninat1expression
AT gotthardtphilipp angiotensiniireceptor1blockagelimitsbraindamageandimprovesfunctionaloutcomeafterbraininjuryinagedanimalsdespiteagedependentreductioninat1expression
AT luhclara angiotensiniireceptor1blockagelimitsbraindamageandimprovesfunctionaloutcomeafterbraininjuryinagedanimalsdespiteagedependentreductioninat1expression
AT huangchangsheng angiotensiniireceptor1blockagelimitsbraindamageandimprovesfunctionaloutcomeafterbraininjuryinagedanimalsdespiteagedependentreductioninat1expression
AT hummelregina angiotensiniireceptor1blockagelimitsbraindamageandimprovesfunctionaloutcomeafterbraininjuryinagedanimalsdespiteagedependentreductioninat1expression
AT schafermichaelke angiotensiniireceptor1blockagelimitsbraindamageandimprovesfunctionaloutcomeafterbraininjuryinagedanimalsdespiteagedependentreductioninat1expression
AT thalsergec angiotensiniireceptor1blockagelimitsbraindamageandimprovesfunctionaloutcomeafterbraininjuryinagedanimalsdespiteagedependentreductioninat1expression